Novo Nordisk’s obesity drug Wegovy was approved in China on Tuesday, though the company has not announced launch plans and starter doses in the U.S. have been in short supply for months.

SHANGHAI, June 25 (Reuters) - Novo Nordisk's (NOVOb.CO), opens new tab hugely popular weight-loss drug Wegovy has been approved in China, it said on Tuesday, the world's second-largest economy and ...

A little over a year after celebrating its 30th anniversary in China with a major production upgrade, Novo Nordisk is back ...

Blockbuster obesity drug Wegovy has been approved in China, opening the door for maker Novo Nordisk NOVO.B1.91%increase; green up pointing triangle to begin selling it in the world’s second ...

You've heard about the likes of Ozempic, Wegovy and Mounjaro, jabs which a growing number of people are taking in an attempt ...

Novo Nordisk has launched its blockbuster Wegovy weight-loss drug in China, adding the world’s second-largest economy to its growing list of markets where appetite for the drugs are rising. The ...

American depositary receipts (ADRs) of Danish drugmaker Novo Nordisk rose Tuesday after the company announced that its popular weight-loss drug Wegovy has been approved to start being sold in China.

Novo gained approval for Wegovy in China in June and will initially target Chinese patients willing to pay out-of-pocket for the weekly injectable drug. Novo ( NVO ) launched Wegovy in the US in 2021.

Novo announced on Monday a $4.1 billion investment to build a U.S. facility to fill injection pens for Wegovy and Ozempic. Ozempic won approval from China in 2021, and Novo saw sales of the drug ...

China has approved Novo Nordisk A/S’s blockbuster Wegovy for chronic weight management, opening up competition for next-generation obesity drugs in the world’s second-largest economy.

Novo Nordisk said Tuesday that its Wegovy weight loss treatment has been approved in China for long-term weight management, opening up the blockbuster drug for sale in the world's second largest ...